June 2016 | HCC Monitor

Initial Phase III Data Shows Regorafenib's Efficacy in Pretreated HCC: Q&A with Ghassan Abou-Alfa, MD

June 06, 2016

Clinical Articles

Regorafenib may soon become another successful treatment for patients with unresectable hepatocellular carcinoma, following the demonstration of prolonged survival with the multikinase inhibitor versus best support care in the phase III RESORCE trial. 

Direct-Acting Antiviral Treatment Linked with HCC Recurrence for Patients with Hepatitis C Infection

July 06, 2016

Clinical Articles

Data from 2 recent studies indicate that patients infected with hepatitis C virus (HCV) who were treated with direct-acting antiviral (DAA) therapy were more likely to experience a recurrence of hepatocellular carcinoma (HCC) than those who had no previous history of the disease.

Dexamethasone Regimen Eases TACE Side Effects

July 06, 2016

Clinical Articles

Treatment with a dexamethasone regimen reduced the incidence of transcatheter arterial chemoembolization associated fever, nausea, vomiting, and anorexia in patients with hepatocellular carcinoma.